N85.03 Endometrial hyperplasia with atypia

Name of the Condition

• Endometrial hyperplasia with atypia

Summary

Endometrial hyperplasia with atypia is a precancerous condition characterized by abnormal thickening of the uterine lining (endometrium) with cellular changes that increase the risk of progression to endometrial cancer. It results from uncontrolled cell growth due to hormonal imbalances, particularly excess estrogen without sufficient progesterone. This condition requires prompt evaluation and management to reduce cancer risk.

Causes

The primary cause is an imbalance between estrogen and progesterone, where estrogen promotes endometrial growth without adequate progesterone to regulate it. This imbalance may stem from conditions like anovulation, obesity, or estrogen-producing tumors. The presence of atypical cells indicates a higher malignant potential compared to non-atypical hyperplasia.

Risk Factors

• Obesity, which increases estrogen production
• Polycystic ovary syndrome (PCOS)
• Estrogen-only hormone therapy without progesterone
• Late menopause
• Nulliparity (never having given birth)
• Family history of endometrial or colorectal cancer
• Diabetes or insulin resistance

Symptoms

• Abnormal uterine bleeding, such as heavy or prolonged menstrual periods
• Bleeding between periods (intermenstrual bleeding)
• Postmenopausal bleeding
• Pelvic pain or pressure in some cases

Diagnosis

Diagnosis typically involves a combination of clinical evaluation and diagnostic tests. A transvaginal ultrasound may be used to assess endometrial thickness, followed by an endometrial biopsy to examine cellular changes for atypia. Hysteroscopy may be performed to visualize the uterine cavity and guide biopsy sampling. Pathological analysis of the biopsy confirms the presence of atypical cells.

Treatment Options

Treatment aims to reduce cancer risk and may include progestin therapy (hormonal treatment) to counteract estrogen effects, or hysterectomy for those at high risk or who do not respond to hormonal therapy. Regular monitoring with repeat biopsies may be recommended to assess treatment response.

Prognosis and Follow-Up

With appropriate management, the risk of progression to endometrial cancer is reduced, but ongoing follow-up is essential. Prognosis depends on the extent of atypia and response to treatment. Regular gynecological evaluations and imaging may be necessary to monitor for recurrence or progression.

Complications

The primary complication is progression to endometrial cancer if left untreated. Other risks include persistent abnormal bleeding, anemia from heavy menstrual bleeding, and potential infertility in reproductive-age individuals.

Lifestyle & Prevention

Maintaining a healthy weight, managing hormonal imbalances, and avoiding unopposed estrogen therapy can help reduce risk. Regular exercise and a balanced diet may support overall hormonal health. For those with PCOS or other risk factors, working with a healthcare provider to manage symptoms is important.

When to Seek Professional Help

Seek medical attention for abnormal uterine bleeding, especially postmenopausal bleeding, or if symptoms persist despite treatment. Prompt evaluation is critical for early detection and management of atypical hyperplasia.

Tips for Medical Coders

When coding for endometrial hyperplasia with atypia (N85.03), ensure documentation supports the presence of atypical cellular changes. Verify that the diagnosis is clearly differentiated from non-atypical hyperplasia or other uterine conditions. Include details on biopsy results, hormonal evaluations, or treatment plans to support code specificity.